Top of this page
Skip navigation, go straight to the content
UCB augments its scientific standing in the targeting of protein-protein interactions with small molecules through back-to-back new publications in Nature Communications. You can read the publications here (https://t.co/FhPYdqEjal) and here (https://t.co/
— UCB News (@ucb_news) 03.03.2021
Our new collaboration with Microsoft will equip us to meet the world’s biggest healthcare challenges. I can truly dare to hope we are standing at the edge of a new dawn in how we develop life-changing therapies https://t.co/5oV3V0Hvpa https://t.co/c8WLpP1
— UCB News (@ucb_news) 02.03.2021
UCB is committed to better understanding the unique experiences and needs of people living with rare diseases. Thank you for sharing your stripes on #RareDiseaseDay. Through your support and our collaborative efforts we will continue to shine a light on r
— UCB News (@ucb_news) 01.03.2021
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017